(EMAILWIRE.COM, April 27, 2012 ) Denmark -- Azanta was nominated Finalist for the 2012 Red Herring Top 100 Europe Award.
Hellerup, Denmark; April 18, 2012 – Azanta A/S announced today it has been selected as a Finalist for Red Herring's Top 100 Europe award, a prestigious list honoring Europe’s most promising private technology ventures of the year.
The Red Herring editorial team has selected the most innovative companies from a pool of hundreds from across Europe. Azanta and the other nominees are evaluated on both quantitative and qualitative criteria, such as financial performance, technology innovation, quality of management, execution of strategy, and integration into their respective industries.
This unique assessment of potential is complemented by a review of the actual track record and standing of Azanta and other companies, which allows Red Herring to see past the “buzz” and make the list a valuable instrument for discovering and advocating the greatest business opportunities in the industry.
"This year was very rewarding," said Alex Vieux, publisher and CEO of Red Herring. "The global economic situation has abated and there are many great companies producing really innovative and amazing products. We had a very difficult time narrowing the pool and selecting the finalists. Azanta A/S shows great promise therefore deserves to be among the Finalists. Now we’re faced with the difficult task of selecting the Top 100 winners of Red Herring Europe. We know that the 2012 crop will grow into some amazing companies that are sure to make an impact."
“Azanta A/S is very proud of the nomination,” said Claus Møller, CEO of Azanta A/S. “The nomination is an encouraging event for Azanta and our team of committed employees and it strongly stimulates us to continue our strategy to develop and supply important niche oncology medications while maintaining a focus on being a commercial operation.”
Azanta and the other finalists are invited to present their winning strategies at the Red Herring Europe Forum in Amsterdam, April 23-25, 2012. The Top 100 winners will be announced at a special awards ceremony the evening of April 25 at the event.
Azanta A/S is a specialty pharma company primarily operating within oncology, women's health and addiction medicine. The vision of Azanta A/S is to become an international market leader within specialty pharma products and innovative pharmaceutical concepts. Azanta A/S currently markets or makes available nine specialty pharma products, including Nimoral, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy. In addition, Azanta A/S has a portfolio of low risk development project for commercialization within the next two to three years.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: